Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of management option on out-of-pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis.
Lindsay D, Schofield P, Nabukalu D, Roberts MJ, Yaxley J, Quinn S, Richards N, Frydenberg M, Gardiner R, Lawrentschuk N, Juraskova I, Murphy DG, Gordon LG. Lindsay D, et al. Among authors: frydenberg m. Aust Health Rev. 2024 Feb;48:172-181. doi: 10.1071/AH23231. Aust Health Rev. 2024. PMID: 38342484 Clinical Trial.
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial.
Hofman MS, Kasivisvanathan V, Link E, Buteau J, Roberts MJ, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Iravani A, Williams S, O'Brien J, Lawrentschuk N, Murphy DG. Hofman MS, et al. Among authors: frydenberg m. Eur Urol Oncol. 2024 Nov 28:S2588-9311(24)00251-7. doi: 10.1016/j.euo.2024.11.006. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39613566 Free article.
Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care.
Lindsay D, Schofield P, Roberts MJ, Yaxley J, Quinn S, Richards N, Frydenberg M, Gardiner R, Lawrentschuk N, Juraskova I, Murphy DG, Collins LG. Lindsay D, et al. Among authors: frydenberg m. Eur Urol Oncol. 2024 Aug 23:S2588-9311(24)00189-5. doi: 10.1016/j.euo.2024.08.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39181775
Standardized template for clinical reporting of PSMA PET/CT scans.
Esfahani SA, Morris MJ, Sartor O, Frydenberg M, Fanti S, Calais J, Vapiwala N. Esfahani SA, et al. Among authors: frydenberg m. Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):335-341. doi: 10.1007/s00259-024-06857-w. Epub 2024 Aug 15. Eur J Nucl Med Mol Imaging. 2024. PMID: 39143250 Free PMC article.
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry.
Bangma C, Doan P, Zhu L, Remmers S, Nieboer D, Helleman J, Roobol MJ, Sugimoto M, Chung BH, Lee LS, Frydenberg M, Klotz L, Peacock M, Perry A, Bjartell A, Rannikko A, Van Hemelrijck M, Dasgupta P, Moore C, Trock BJ, Pavlovich C, Steyerberg E, Carroll P, Koo KC, Hayen A, Thompson J; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Bangma C, et al. Among authors: frydenberg m. Eur Urol Oncol. 2024 Jul 17:S2588-9311(24)00176-7. doi: 10.1016/j.euo.2024.07.003. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39025687 Free article.
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
See AW, Conway P, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Pranavan G, Peters J, Smyth LML, Gwini SM, McKenzie DP, Bowden P. See AW, et al. Among authors: frydenberg m. Int J Cancer. 2024 Oct 1;155(7):1248-1256. doi: 10.1002/ijc.35052. Epub 2024 Jun 19. Int J Cancer. 2024. PMID: 38898626 Clinical Trial.
The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, Helfand BT, Talaty P, Ong KR, Douglas E, Cook J, Rosario DJ, Salinas M, Buys SS, Anson J, Davidson R, Longmuir M, Side L, Eccles DM, Tischkowitz M, Taylor A, Cruellas M, Ballestero EP, Cleaver R, Varughese M, Barwell J, LeButt M, Greenhalgh L, Hart R, Azzabi A, Jobson I, Cogley L, Evans DG, Rothwell J, Taylor N, Hogben M, Saya S; IMPACT Study Steering Committee; IMPACT Collaborators; Eeles RA, Aaronson NK. Bancroft EK, et al. BJU Int. 2024 Sep;134(3):484-500. doi: 10.1111/bju.16432. Epub 2024 Jun 5. BJU Int. 2024. PMID: 38839570
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. Emmett L, et al. Among authors: frydenberg m. J Urol. 2024 Aug;212(2):299-309. doi: 10.1097/JU.0000000000004010. Epub 2024 May 17. J Urol. 2024. PMID: 38758680
344 results